Business Context and Reporting Period
Company: Compugen Ltd.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Date: September 17, 2013
Context: The filing discloses the issuance of a press release regarding experimental data for CGEN-15049, a novel immune checkpoint protein identified through the Company's predictive discovery infrastructure.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on scientific developments and does not contain financial statements or operational metrics.
Material Changes
Scientific Development: The Company announced experimental data for CGEN-15049. This compound is one of nine novel immune checkpoint proteins predicted to date by Compugen's unique predictive discovery infrastructure.
Guidance, Outlook, and Risks
Management Commentary: The filing incorporates by reference a press release detailing the experimental data. No specific financial guidance, future outlook, or risk factors are explicitly detailed within the body of this Form 6-K text.
Unusual Items: None reported in this specific filing text.
Investor Verification Checklist
- Review the full text of the press release (Exhibit 99.1) for specific details on the experimental data for CGEN-15049.
- Verify the status of the other eight novel immune checkpoint proteins mentioned in the filing.
- Check the Company's Registration Statements on Form F-3 (File Nos. 333-171655 and 333-185910) where this information is incorporated by reference.
- Confirm the clinical or pre-clinical stage of CGEN-15049 based on the referenced press release.